Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17 21 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given an average recommendation of “Hold” by the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 3,140,000 shares, a growth of 52.4% from the July 31st total of 2,060,000 shares. Based on an average daily volume of 244,800 shares, the days-to-cover ratio […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) had its target price cut by Morgan Stanley from $7.00 to $5.00 in a report published on Monday morning, MarketBeat Ratings reports. They currently have an underweight rating on the stock. Several other research analysts also recently commented on the company. Bank of America lifted their target price on […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) – Investment analysts at Wedbush issued their FY2027 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research report issued on Wednesday, May 10th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.42) per share for the year. Wedbush has a “Outperform” rating […]